VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 06, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in two upcoming investor conferences.
• Cowen 37th Annual Health Care Conference, March 6-8, 2017, Boston, MA
• Barclays Global Healthcare Conference, March 14-16, 2017, Miami, FL
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.